Physician

Adnan Ahmad Khan, M.D.

According to 2025 Medicare claims, Adnan Khan, M.D. (NPI: 1477717585) practices nephrology in the San Diego-Chula Vista-Carlsbad, CA market, with the plurality of this provider's patient population coming from San Diego, CA. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1003934803; TIN: 237064656) and primary practice location at 92037-1300.

Khan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 292 traditional Medicare patients, billed 1,549 HCPCS/CPT codes, and received $112,221 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,447 prescription claims across 205 beneficiaries totaling $234,055 in drug costs, led by Lokelma (Sodium Zirconium Cyclosilicate). DME data shows 1,516 claims. Open Payments data shows 4 records totaling $162. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $17,464 to $112,221. Similarly, Part D prescription costs have risen steadily, from $41,840 to $234,055. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $3,362 to $1,883.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	137	293	$17,464
2016	256	764	$51,785
2017	254	878	$55,457
2018	368	940	$82,671
2019	388	1,400	$146,222
2020	350	1,146	$120,923
2021	362	1,605	$154,138
2022	411	3,389	$173,024
2023	317	1,323	$110,746
2024	292	1,549	$112,221

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	132	639	$41,840
2016	252	3,144	$167,166
2017	229	3,774	$222,217
2018	273	3,155	$208,745
2019	308	2,578	$300,707
2020	223	1,571	$188,299
2021	189	1,323	$181,168
2022	198	1,344	$301,638
2023	204	1,272	$275,739
2024	205	1,447	$234,055

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	66	473	$20,594
2016	25	104	$3,192
2017	N/R	23	$975
2018	261	685	$36,525
2019	619	2,546	$167,919
2020	438	1,776	$123,320
2021	579	2,404	$186,051
2022	519	1,877	$148,791
2023	392	1,357	$73,081
2024	349	1,516	$108,939

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	23	24	$178
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	44	49	$140
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	206	404	$140
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	70	317	$96
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	146	281	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lokelma	Sodium Zirconium Cyclosilicate	43	1,559	$36,104
Valganciclovir Hcl	Valganciclovir Hcl	92	3,027	$24,184
Trulicity	Dulaglutide	15	424	$13,307
Veltassa	Patiromer Calcium Sorbitex	12	420	$13,249
Tradjenta	Linagliptin	26	780	$11,058

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	28	148	$79,527
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	97	443	$5,726
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	90	297	$5,458
J7507	Tacrolimus, immediate release, oral, 1 mg	N	50	196	$4,887
J7518	Mycophenolic acid, oral, 180 mg	N	17	69	$3,999

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$162	Ethicon Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adnan Ahmad Khan, M.D.?

Tedicare shows public-source Medicare data for Adnan Ahmad Khan, M.D. (NPI 1477717585), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adnan Ahmad Khan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adnan Ahmad Khan, M.D.?

Adnan Ahmad Khan, M.D. is linked to REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1003934803) in the available physician profile data.

Does Adnan Ahmad Khan, M.D. have Open Payments data?

Adnan Ahmad Khan, M.D. has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.